AtaiBeckley (ATAI) Receivables - Other (2020 - 2026)

AtaiBeckley (ATAI) reported Receivables - Other of $326000.0 for Q3 2021, down 63.78% sequentially from $900000.0 in Q4 2020.

AtaiBeckley (ATAI) Receivables - Other (2020 - 2026) Analysis & Trends

AtaiBeckley's Receivables - Other history runs 1 years deep, the most recent figure standing at $600000.0 for Q1 2026.

For the quarter ending Q3 2021, Receivables - Other changed N/A year-over-year to $326000.0; the trailing twelve-month figure through Sep 2021 stood at $326000.0 (changed N/A YoY), and the FY2020 full-year result was $900000.0, changed N/A from the prior year.
Receivables - Other steadied at $600000.0 in Q1 2026 per ATAI's latest filing.
In the past five years, Receivables - Other ranged from a high of $900000.0 in Q4 2020 to a low of $326000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-

Download Data